Meg Hooton

R&D

Meg Hooton, President of IQVIA Biotech, leads the organisation, providing clinical development solutions for biotech and emerging biopharma clients.

News

Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.